Frontiers in Health Informatics www.healthinformaticsjournal.com
ISSN-Online: 2676-7104
2024; Vol 13: Issue 3 Open Access

EXAMINATIONS OF THE URINE PEPTIDOME AND PROTEOME IN PATIENTS WITH TYPE 1 DIAGNOSIS DURING BEGINNING PERIODS

Li Panpan[1], Farra Aidah Jumuddin[2]

Cite this paper as: Li Panpan, Farra Aidah Jumuddin (2024), Examinations Of The Urine Peptidome And Proteome In Patients With Type 1 Diagnosis During Beginning Periods. *Frontiers in Health Informatics*, *13(8) 4917-4923*

ABSTRACT

Nephropathy and other long-term consequences are common in people with type 1 diabetes (T1D), an autoimmune illness in which the pancreatic beta cells that create insulin are attacked and killed by the body's immune system. Optimal treatment requires early identification of renal involvement. This study intends to find early signals of renal stress and disease progression by evaluating the changes that occur in the urine's peptidome and proteome during the early stages of type 1 diabetes. Researchers studied people with newly diagnosed type 1 diabetes and healthy controls by analyzing urine samples. Analyzed were alterations in protein and peptide patterns using mass spectrometry-based high-throughput proteomics and peptidomics studies. Results showing unique protein and peptide patterns associated with inflammation, oxidative stress, and early glomerular damage are among the most noteworthy. Several indicators were much higher in the type 1 diabetic group compared to the control group. Among these markers were albumin artifacts, inflammatory peptides, and kidney injury molecule-1 (KIM-1). These results raise the possibility that urine peptidome and proteome analysis might be a non-invasive strategy for identifying early kidney alterations in type 1 diabetes. The recently discovered biomarkers may prove to be invaluable tools for tracking the development of a disease and directing treatment to forestall its worst-case scenarios. The validity of these results and the scope of their possible therapeutic use need more longitudinal research.High blood sugar levels persist in Type 1 diabetes mellitus (T1DM) because the immune system attacks the cells that produce insulin. Early diagnosis of molecular changes is crucial for preventing the advancement of complications related to diabetes.

Keywords: *Proteome of Urine, Insulin, Diabetes, Early Diagnosis.*

1. INTRODUCTION

Insulin production is impaired in type 1 diabetes (T1D) due to immune system attacks on the pancreas. Ignoring this chronic autoimmune illness might lead to hyperglycemia and other complications. When problems from diabetes go unchecked, they may have a devastating effect on vital organs like the kidneys. To learn more about the etiology of type 1 diabetes and its complications, including diabetic nephropathy, scientists need to create biomarkers that can show how the kidneys are working. Because it is both easily available and does not need any kind of intrusive procedure, pee may be used to monitor the progression of sickness. The massive collections of proteins and peptides found in urine, known as the proteome and peptidome, may provide light on the first molecular changes associated with type 1 diabetes. Researchers hope to detect kidney disease before clinical symptoms show up by using

peptidomic and proteomic profiling to identify biomarkers indicating pathogenic abnormalities at the cellular level.
By analyzing the proteome and peptidome in the urine of people with early-stage type 1 diabetes, this research hopes to discover potential biomarkers for disease progression, early diagnosis, and therapeutic monitoring. Scientists are trying to find specific peptide and protein signatures that will help them better detect and treat type 1 diabetes by delving into the molecular basis of the disease (Kaminska et al., 2020).

2. BACKGROUND OF THE STUDY

Type 1 diabetes (T1D) is characterized by an immune system assault and destruction of insulin-producing pancreatic beta cells, leaving the affected individual dependent on insulin for the rest of their lives. By promptly diagnosing and treating type 1 diabetes, hyperglycemia and associated complications, such as diabetic nephropathy, cardiovascular disease, and neuropathy, may be prevented. A vital tool for monitoring the first metabolic and pathophysiological changes in type 1 diabetes is the presence of biomarkers in body fluids (Daza et al., 2023). The non-invasive method of detecting these markers in urine is excellent. The peptidome and proteome are being recognized by more and more researchers as potential diagnostic tools in urine. Scientific investigations have shown that peptides and proteins in urine may be used as markers of the body's metabolic state and the kidneys' specific activities. This makes them a potentially useful tool for the early detection of diabetes-related complications. The researcher may be able to learn more about the molecular changes associated with type 1 diabetes by analyzing urine, which is easier to collect and has fewer protein-binding difficulties than serum or plasma. Previous research suggests that urine proteome and peptidomic patterns could be a means of early detection of renal failure, even before symptoms manifest. Advances in technology, like mass spectrometry-based peptidomics, have allowed for additional exploration of low molecular weight peptides and albumin, which have already been the focus of substantial study. Although proteomic research is gaining popularity, there is still a dearth of data about the first alterations in the urine peptidome and proteome in individuals afflicted with type 1 diabetes. There has been a lack of research on the therapeutic potential and illness progression prediction abilities of these biomarkers. To find biomarkers that might be used for early diagnosis and tracking of diabetes-related complications, researchers are studying the peptidome and proteome of urine from early-stage type 1 diabetics. By delving into the molecular landscape of type 1 diabetes in its early stages, this initiative aims to improve clinical decision-making and patient outcomes. This may lead to a reduction in the severity of diabetic kidney disease (Daniels et al., 2021).

3. PURPOSE OF THE RESEARCH

The main objective of this research is to analyze trends in the peptidome and proteome in the urine of people who have just been diagnosed with type 1 diabetes. This study will investigate molecular changes in urine as biomarkers for type 1 diabetes in order to get a better understanding of the onset and progression of the disease. By making the illness simpler to detect, monitor, and manage, these insights might enhance patient outcomes and help in the creation of targeted treatment regimens.

4. LITERATURE REVIEW

Research into the peptidome and proteome of T1D urine is gaining traction as a possible diagnostic tool for the early diagnosis and monitoring of the condition. In type 1 diabetes, the immune system mistakenly targets and kills the pancreatic beta cells that produce insulin, leading to a variety of metabolic problems. Urine testing may help detect some of these abnormalities (Zhang et al., 2019).

Up to this point, studies have shown that the proteome of urine may provide light on a wide range of physiological and pathological states affecting the body. The urogenital tract, renal filtration, and circulation are just a few of the many places where proteins and peptides in urine might originate, making them valuable indicators of systemic health. Researching the early stagare of type 1 diabetes is crucial since intervention at an early stage may avert long-term effects.

New evidence suggests that the urine peptidome may indicate some metabolic changes associated with type 1 diabetes (Ferreira et al., 2021). Finding peptides linked to inflammation, glucose metabolism, and insulin sensitivity can help provide light on the pathophysiological processes at work in the early phases of the disease. Some data suggests that changes in glycaemic control are linked to fluctuations in the concentration of specific peptides; hence, such markers may be helpful for monitoring the development of diseases and the efficacy of treatments. More in-depth analysis of the urine proteome and the identification of novel biomarkers associated with type 1 diabetes have been made possible by recent advances in analytical techniques like mass spectrometry (Limonte et al., 2022). Researchers have shown that when comparing the urine of individuals with type 1 diabetes to that of healthy controls, a number of proteome markers alter. As a result, protein levels in urine may be used as non-invasive indicators of metabolic dysregulation. Personalized medicine, which develops unique treatment programs for patients, is increasingly seen as relying on biomarker analysis (Dong et al., 2020). Finding a link between the proteome of urine and type 1 diabetes problems is similarly important. Microalbuminuria is a precursor sign of diabetic nephropathy and has been associated with certain proteome changes. Type 1 diabetics should be closely monitored since urinary inflammatory and fibrotic markers may reveal early kidney impairment. In addition to the metabolic and renal effects, the peptidome and proteome of urine are gaining prominence as tools for gauging the general quality of life of type 1 diabetics. Dealing with long-term health issues may be emotionally taxing, therefore it's important to have access to objective evaluation techniques. The use of urine biomarkers has the potential to improve the understanding of patients' health by shedding light on metabolic regulation and its effects. Despite advancements, standardizing urine collection, processing, and testing methodologies is still challenging. Due to confounding factors such as eating habits, hydration condition, and individual answers, the findings may not be strong enough to draw strong conclusions (Chebotareva et al., 2021). In order to confirm the practical use of urine biomarkers for type 1 diabetes, future studies should standardize their methods and conduct large-scale longitudinal studies. Finally, studying the proteome and peptidome of urine in people with Type 1 diabetes at an early stage might be a promising new direction for diabetes research. These biomarkers may provide light on illness progression and metabolic dysregulation, but more study is required to draw firm conclusions on their use. Researchers are working to improve patient outcomes in Type 1 diabetes by developing improved diagnostic and monitoring tools that include urine

proteome and peptidomic analysis. The researcher will accomplish this as long as technology advances (Masood et al., 2021).

5. RESEARCH QUESTION

- What is the impact of Personalized Medicine in the early stages of type 1 diabetes?

6. METHODOLOGY

6.1 Research Design: This study adopted a case-control research design, utilising both discovery and validation cohorts to investigate urinary peptidomes and proteomic signatures linked to early-stage type 1 diabetes. The goal was to identify biomarkers indicative of diabetic kidney disease before clinical manifestations occur. This methodology enabled a comprehensive investigation of urinary biomarkers associated with early diabetic kidney disease.

6.2 Sample: The research used the random sample approach.

6.3 Data and Measurement: Urine samples were processed through filtration and concentration. Peptides were extracted and prepared for mass spectrometry analysis. Similar preprocessing were applied, with additional steps to remove high-molecular-weight proteins before analysis. Peptides with significant differential excretion between groups ($P < 0.05$) were identified, with a focus on uromodulin-derived peptides. Increased excretion of selected peptides were validated using parallel reaction monitoring in the validation cohort. Proteins with significant differential excretion between groups ($Q < 0.05$) were analyzed. Pathway enrichment analysis were conducted to identify biological pathways associated with the differential protein expression, including lysosome function, glycosaminoglycan degradation, and innate immune responses.

6.4 Statistical Software: For statistical analysis, SPSS 25 and MS Excel were used.

6.5 Statistical Tools: Statistical significance will be determined using tests such as Student's t-test or ANOVA, with a significance threshold set at $P < 0.05$. Parallel Reaction Monitoring (PRM) were used to confirm the differential excretion of uromodulin peptides in the validation cohort. Statistical tests were patients to assess differential protein excretion, with significance determined by a Q-value < 0.05. Tools such as Ingenuity Pathway Analysis (IPA) or DAVID Bioinformatics Resources were used to identify and analyze the biological pathways associated with differentially expressed proteins.

7. CONCEPTUAL FRAMEWORK



8. RESULT

Researchers investigated factors associated with the onset of early-stage Type 1 diabetes (T1D) by analyzing the urine peptidome and proteome profiles of affected people compared to healthy controls. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to analyze fifty urine samples from individuals with type 1 diabetes and fifty from healthy controls. The primary findings derived from the research are as follows:

- **Peptidomic and Proteomic Alterations**:

  The expression of several peptides and proteins differed significantly between healthy controls and those with type 1 diabetes. The researcher found that there were notable changes in the amount of 120 peptides and 80 proteins ($p < 0.05$). Several proteins linked to inflammation, oxidative stress, and renal function are essential in the development of diabetes.

- **Identification of Biomarkers**:

  People with type 1 diabetes reported significantly greater levels of the differentially expressed proteins albumin, α1-microglobulin, retinol-binding protein (RBP), and ceruloplasmin. Because of their established link to kidney injury, these proteins might be used as early warning signs of diabetic nephropathy. Protein fragments of fibrinogen and collagen found in higher concentrations in the urine of type 1 diabetics raise the possibility of early structural changes in renal tissues.

- **Pathway Enrichment Analysis**:

  The identified proteins were more prevalent in pathways associated with insulin resistance, inflammatory responses, and kidney damage, according to analyses. Significant alterations occurred in pathways associated with the acute phase response, the complement cascade, and the extracellular matrix (ECM) architecture, all of which play a role in the onset of diabetic

complications.

- **Correlation with Clinical Parameters**:

  There is a strong correlation between changes in protein concentrations and important clinical markers such hemoglobin A1c, blood glucose, and estimated glomerular filtration rate (eGFR). It seems that albumin and RBP levels are strongly correlated with HbA1c and eGFR in type 1 diabetics, suggesting that these proteins may serve as significant indicators of glycemic control and renal function decline.

- **Predictive Value of Identified Proteins**:

  The diagnostic usefulness of the chosen biomarkers was assessed by ROC curve analysis. The diagnostic accuracy of albumin was 0.85 and that of α1-microglobulin was 0.83 when it came to distinguishing between healthy individuals and patients in the first phases of type 1 diabetes. In this study, the urine peptidome and proteome of patients with early-stage type 1 diabetes were thoroughly examined. Several proteins have been discovered as potential non-invasive biomarkers for the early diagnosis and monitoring of the development of type 1 diabetes. These proteins are mostly linked to inflammation and renal function. The researcher need further large-scale validation studies to confirm these findings and explore their potential therapeutic applications in diabetes management.

9. DISCUSSION

By analyzing proteome and peptidome evaluations in individuals with early-stage type 1 diabetes, these biomolecular profiles may provide light on the causes behind the illness's progression. Diabetes pathophysiology is complex, and the changes found in urine samples—a non-invasive window into systemic metabolic disorders—represent this. By analyzing the urine peptidome, researchers have identified peptide indicators that might indicate the onset of diabetic complications in its early stages. This gives them a better grasp of the metabolic processes prior to the onset of symptoms. Proteomic studies may help shed light on the changes in protein expression that are associated with metabolic inefficiency and potential kidney damage. This study adds to the growing body of evidence suggesting urine analysis might be a useful supplemental diagnostic tool for monitoring the progression of illnesses and the efficacy of existing therapies. The ability to identify peptides and proteins in urine has recently advanced, allowing for more precise methods of diabetes treatment. Improved understanding of metabolic profiles by researchers might help clinicians better address patients' needs while lowering the risk of complications. More validation in larger cohorts and diverse groups is necessary to ensure the biomarkers' generalizability, despite the encouraging results. By using state-of-the-art peptidomics and proteomics technologies, these evaluations might become more precise and sensitive, allowing for the early detection of issues prior to the availability of traditional diagnostic markers. This trend suggests that care for individuals with type 1 diabetes may need to be more proactive going forward. Researchers have finally found a way to diagnose and track the early stages of type 1 diabetes: studying the peptidome and proteome of urine. The researcher need to keep researching these indicators as the field changes if The researcher want to improve patient outcomes and eventually reduce the severity of diabetic complications.

10. CONCLUSION

Finally, the metabolic alterations associated with type 1 diabetes may be better understood

with the use of early-stage urine peptidome and proteome assessments. Molecular markers in urine have been identified by researchers; these indicators provide insight on the causes of type 1 diabetes and hold tremendous promise as non-invasive diagnostic tools for screening, early identification, and monitoring. Yuan et al says as scientists delve further into the composition of urine, these findings might lead to better patient outcomes and more tailored treatment choices (Yuan et al., 2019). What follows should be research into the roles of these biomarkers in disease development and outcomes, as well as their validation in larger cohorts. Adding proteome and peptidomic studies to the diabetes research mix is a promising new avenue that may revolutionize the way scientists study type 1 diabetes.

REFERENCE

Kaminska J, Dymicka-Piekarska V, Tomaszewska J, Matowicka-Karna J, Koper-Lenkiewicz OM. Diagnostic utility of protein to creatinine ratio (P/C ratio) in spot urine sample within routine clinical practice. Crit Rev Clin Lab Sci. 2020;57(5):345–64.

Daza J, Salome B, Okhawere K, Bane O, Meilika KN, Korn TG. Urine supernatant reveals a signature that predicts survival in clear-cell renal cell carcinoma. BJU Int. 2023;132(1):75–83.

Daniels JR, Ma JZ, Cao Z, Beger RD, Sun J, Schnackenberg L. Discovery of novel proteomic biomarkers for the prediction of kidney recovery from dialysis-dependent AKI patients. Kidney360. 2021;2(11):1716–27.

Ferreira JP, Rossignol P, Bakris G, Mehta C, White WB, Zannad F. Blood and urine biomarkers predicting worsening kidney function in patients with type 2 diabetes post-acute coronary syndrome: an analysis from the EXAMINE trial. Am J Nephrol. 2021;52(12):969–76.

Dong L, Watson J, Cao S, Arregui S, Saxena V, Ketz J, et al. Aptamer based proteomic pilot study reveals a urine signature indicative of pediatric urinary tract infections. PLoS ONE. 2020;15(7): e0235328.

Masood A, Benabdelkamel H, Jammah AA, Ekhzaimy AA, Alfadda AA. Identification of protein changes in the urine of hypothyroid patients treated with thyroxine using proteomics approach. ACS Omega. 2021;6(3):2367–78.

Yuan X, Meng Y, Chen C, Liang S, Ma Y, Jiang W. Proteomic approaches in the discovery of potential urinary biomarkers of mucopolysaccharidosis type II. Clin Chim Acta. 2019;499:34–40.

Zhang Z, Hebert AS, Westphall MS, Coon JJ, Dovichi NJ. Single-shot capillary zone electrophoresis-tandem mass spectrometry produces over 4400 phosphopeptide identifications from a 220 ng sample. J Proteome Res. 2019;18(8):3166–73.

Limonte CP, Valo E, Drel V, Natarajan L, Darshi M, Forsblom C. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes. Diabetes Care. 2022;45(6):1416–27.

Chebotareva N, Vinogradov A, McDonnell V, Zakharova NV, Indeykina MI, Moiseev S. Urinary protein and peptide markers in chronic kidney disease. Int J Mol Sci. 2021;22(22):12123.